Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Operating Leases (2016 - 2025)

Historic Operating Leases for Lineage Cell Therapeutics (LCTX) over the last 12 years, with Q3 2025 value amounting to $1.5 million.

  • Lineage Cell Therapeutics' Operating Leases fell 117.42% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 117.42%. This contributed to the annual value of $1.3 million for FY2024, which is 3456.29% down from last year.
  • Lineage Cell Therapeutics' Operating Leases amounted to $1.5 million in Q3 2025, which was down 117.42% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Operating Leases ranged from a high of $2.9 million in Q4 2022 and a low of $1.0 million during Q1 2025
  • Moreover, its 5-year median value for Operating Leases was $2.0 million (2023), whereas its average is $1.9 million.
  • In the last 5 years, Lineage Cell Therapeutics' Operating Leases soared by 4734.67% in 2022 and then plummeted by 5115.72% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Operating Leases (Quarter) stood at $1.9 million in 2021, then skyrocketed by 47.35% to $2.9 million in 2022, then crashed by 30.8% to $2.0 million in 2023, then tumbled by 34.56% to $1.3 million in 2024, then grew by 16.99% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.1 million for Q2 2025, and $1.0 million during Q1 2025.